nal Application No. PCT/GB2004/002871

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K16/00 A61K A61K39/395 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K A61K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, Sequence Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 98/37200 A (GENENTECH, INC: HSEI, 1-23 VANESSA; KOUMENIS, IPHIGENIA; LEONG, 31-38, STEVEN, R;) 27 August 1998 (1998-08-27) "ANTIBODY FRAGMENT-POLYMER CONJUGATES AND 41 - 43HUMANIZED ANTI-IL-8 MONOCLONAL ANTIBODIES" page 21, line 4 - line 9
page 23, line 9 - page 27, line 18
page 30, line 30 - page 31, line 10
page 41, line 29 - line 37 claim 14 -/--X Further documents are listed in the continuation of box C. Patent family members are listed in annex. X Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but *A* document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date *L¹ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art. *O* document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 2 5. 07. 2005 12 July 2005 Name and mailing address of the ISA **Authorized officer** European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Niebuhr-Ebel, K

Ini onal Application No
Pul/GB2004/002871

ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 97/36932 A (PHARMACIA & UPJOHN AB; ANTONSSON, PER; HANSSON, JOHAN; BJOERK, PER; DO) 9 October 1997 (1997-10-09) "MODIFIED/CHIMERIC SUPERANTIGENS AND THEIR USE" page 14, line 28 - line 33 page 19, line 1 - line 11 claim 27	1-23, 31-38, 41-43
WO 99/15549 A (CELLTECH THERAPEUTICS LTD; HUMPHREYS DAVID PAUL (GB)) 1 April 1999 (1999-04-01) "PEPTIDE SEQUENCES AS HINGE REGIONS IN PROTEINS LIKE IMMUNOGLOBULIN FRAGMENTS AND THEIR USE IN MEDICINE" page 15, line 16 - line 26 page 30: table II	1-23, 31-38, 41-43
page 20, line 22 - line 32	32-38
BURMEISTER GETZ E ET AL: "COMPARISON BETWEEN THE SULFHYDRYL REDUCTANTS TRIS(2-CARBOXYETHYL)PHOSPHINE AND DITHIOTHREITOL FOR USE IN PROTEINBIOCHEMISTRY" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 273, 15 August 1999 (1999-08-15), pages 73-80, XP000946001 ISSN: 0003-2697 abstract page 73, right-hand column, last paragraph - page 74, paragraph 3 discussion	32-38
SINGH RAJEEVA ET AL: "Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 304, no. 2, 2002, pages 147-156, XP001165655 ISSN: 0003-2697 abstract figure 1 page 155, left-hand column, paragraph 2 - right-hand column, paragraph 1	24-41,43
	WO 97/36932 A (PHARMACIA & UPJOHN AB; ANTONSSON, PER; HANSSON, JOHAN; BJOERK, PER; DO) 9 October 1997 (1997-10-09) "MODIFIED/CHIMERIC SUPERANTIGENS AND THEIR USE" page 14, line 28 - line 33 page 19, line 1 - line 11 claim 27 WO 99/15549 A (CELLTECH THERAPEUTICS LTD; HUMPHREYS DAVID PAUL (GB)) 1 April 1999 (1999-04-01) "PEPTIDE SEQUENCES AS HINGE REGIONS IN PROTEINS LIKE IMMUNOGLOBULIN FRAGMENTS AND THEIR USE IN MEDICINE" page 30; table II page 20, line 22 - line 32 BURMEISTER GETZ E ET AL: "COMPARISON BETWEEN THE SULFHYDRYL REDUCTANTS TRIS(2-CARBOXYETHYL)PHOSPHINE AND DITHIOTHREITOL FOR USE IN PROTEINBIOCHEMISTRY" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 273, 15 August 1999 (1999-08-15), pages 73-80, XP000946001 ISSN: 0003-2697 abstract page 73, right-hand column, last paragraph - page 74, paragraph 3 discussion SINGH RAJEEVA ET AL: "Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 304, no. 2, 2002, pages 147-156, XP001165655 ISSN: 0003-2697 abstract figure 1 page 155, left-hand column, paragraph 2 - right-hand column, paragraph 1

Inte onal Application No PC I / GB 2004/002871

		FC1/GB2004/0028/1		
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	LEONG S R ET AL: "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation" CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 16, no. 3, 7 November 2001 (2001-11-07), pages 106-119, XP002314089 ISSN: 1043-4666	41		
A	the whole document	20-40,43		
P,X	WO 2004/043492 A (BRACCO IMAGING S.P.A; DE HAEN, CHRISTOPH; MAISANO, FEDERICO) 27 May 2004 (2004-05-27) abstract page 11, line 20 - page 12, line 12 page 23; examples 3-5 claim 1	24-41,43		

tional application No. PCT/GB2004/002871

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-23 and 42 (completely) and 31-38, 41 and 43 (in part)

Antibody Fab' or Fab fragment, characterized in that the interchain cysteine of CH1, CL or both have been replaced by another amino acid.

2. claims: 24-30, 39 and 40 (completely) and 31-38, 41 and 43 (in part)

Antibody Fab or fab' fragment, characterized in that the heavy chain is not covalently bonded to the light chain, and to which two or more effector molecules are attached, at least one to each of the interchain cysteines

INTERNATIONAL SEARCH REPORT formation on patent family members

inte nal Application No PCT7GB2004/002871

Patent document sited in search report		Publication date		Patent family member(s)	Publication date
WO 9837200	Α	27-08-1998	US	6117980 A	
			EP	1415998 A	
			WO AT	9837200 A 258599 T	2 27-08-1998 15-02-2004
			AU	2559799 A	
			AU	746819 B	
			AU	6535798 A	
			BR	9807464 A	
			CA	2281794 A	
			CN	1297480 A	
			DE	69821338 D	
			DE	69821338 T	2 21-10-2004
			DK	968291 T	
			EP	0968291 A	
			ES	2215295 T	
			JP	2001512489 T	
			NZ	336839 A	
			NZ	511956 A	
			PT	968291 T	
			WO US	9937779 A 6870033 B	
			ZA	9900319 A	
WO 9736932	A	09-10-1997	AT	294818 7	15-05-2005
			ΑU	707827 E	
			ΑU	2525197 <i>F</i>	
			BR	9702179 <i>F</i>	
			CA	2222757 <i>I</i>	
			CZ	9703712 A	
			DE	69733179 [
			DK Ep	835266	
			ID	0835266 / 16512 /	
			JP	2002502363	
			NO	975435	
			NZ	329145	
			PL	323626	
			RU	2198895	C2 20-02-2003
			WO	9736932	A1 09-10-1997
			TW	517061	
			US	2003092894	
			US Za	6514498 9702492	
WO 9915549	 A	01-04-1999	AT	257160	T 15-01-2004
3310013	• • •	U_ U. 2222	ΑÙ	9174398	
			DE	69820885	
			DE	69820885	
			ΕP	1015495	A2 05-07-2000
			ES	2212340	T3 16-07-2004
			WO	9915549	
			JP	2001517423	
			US	6642356 	B1 04-11-2003
WO 2004043492	Α	27-05-2004	EP	1419786	
			AU	2003288022 2004043492	
			WQ		